AIM: To observe the efficacy of first Ranibizumab intravitreal injection on macular edema caused by retinal vein occlusion(RVO).

METHODS: Thirty-nine eyes of 39 patients with macular edema due to RVO were treated in our hospital during June 2014 to December 2014. Patients received intravitreal injection of 0.05mL ranibizumab. Best corrected visual acuity(BCVA), central macular thickness(CMT)and cube average thickness(CAT)were analyzed at 2d, 2, and 4wk after injection, respectively.

RESULTS: The baseline BCVA(LogMAR), CMT and CAT were 0.82±0. 45, 541±136μm and 382±107μm before treatment. After first ranibizumab intravitreal injection, mean BVCA significantly improved at 2d(0. 56±0.35,P<0.01), 2wk(0.48±0.39,P<0.01), 4wk(0.51±0.44, P<0.01), compared to baseline BCVA. Mean CMT also decreased at 2d(372±86μm, P<0.01), 2wk(281±74μm, P<0.01), 4wk(286±97μm, P<0.01), mean CAT also decreased at 2d(331±46μm, P<0.01), 2wk(312±54μm, P<0.01), 4wk(319±68μm, P<0.01), compared to baseline BCVA.

CONCLUSION: First intravitreal injection of ranibizumab can improve macular edema caused by RVO in short-term, but long-term effects is needed further observed.